medigraphic.com
ISSN 2992-8036 (Electronic)
ISSN 2306-4102 (Print)
Órgano Oficial del Colegio Mexicano de Ortopedia y Traumatología

2020, Number 3

<< Back Next >>

Acta Ortop Mex 2020; 34 (3)

Prevalence in Mexico of giant cell tumor, osteosarcoma and chondrosarcoma (2013-2017)

Rivas-Berny C, Méndez-Domínguez N, Alejos-Gómez R

Language: Spanish
References: 17
Page: 183-188
PDF size: 179.95 Kb.


ABSTRACT

Introduction: Primary bone tumors make up 1% of cancers in adults, the most common being osteosarcoma and chondrosarcoma. Giant cell tumor (GCT) is a locally aggressive benign neoplasm, accounting for 4-10% of all primary bone tumors, but in certain populations it accounts for up to 20%. The main objective of this work was to determine the proportion of GCTs, osteosarcomas and chondrosarcomas in a period of five years, and describe the characteristics of the patients from whom they come. Clinical implications: More information about the epidemiology of bone tumors is required to know their epidemiology in the Mexican population. Material and methods: Descriptive observational study of a retrospective cross section including all patients who underwent surgery for tumoral resection, in public hospitals at national level, and whose histopathological pieces were processed and resulted in tissue compatible with a) GCT, b) osteosarcomas and c) chondrosarcomas. Results: Between 2013 and 2017, 138 cases of the three primary bone tumors studied were reported, giant cell tumor (50%), osteosarcoma (25.36%) and chondrosarcoma (24.64%). The states with the highest number of cases were the state of Mexico (45.65%) and Mexico City (26.81%). Women had a higher prevalence (57.25%) than men (42.75%). The average age of presentation of the tumors was 36.80 years. Conclusions: GCT is not an uncommon tumor in the Mexican population, since it has its own characteristics.


REFERENCES

  1. Flanagan A, Lindsay D. A diagnostic approach to bone tumours. Pathology. 2017; 49(7): 675-87. doi: 10.1016/j.pathol.2017.08.003.

  2. Kumar N, Gupta B. Global incidence of primary malignant bone tumors. Curr Orthop Pract. 2016; 27(5): 530-4. doi: 10.1097/BCO.0000000000000405.

  3. Mavrogenis A, Igoumenou V, Megaloikonomos P, Panagopoulos G, Papagelopoulos P, Soucacos P. Giant cell tumor of bone revisited. SICOT J. 2017; 3: 54. doi: 10.1051/sicotj/2017041.

  4. Lin F, Hu Y, Zhao L, Zhang H, Yu X, Wang Z, et al. The epidemiological and clinical features of primary giant cell tumor around the knee: a report from the multicenter retrospective study in china. J Bone Oncol. 2016; 5(1): 38-42. doi: 10.1016/j.jbo.2016.02.001.

  5. Amelio JM, Rockberg J, Hernandez RK, Sobocki P, Stryker S, Bach BA, et al. Population-based study of giant cell tumor of bone in Sweden (1983-2011). Cancer Epidemiol. 2016; 42: 82-89. doi: 0.1016/j.canep.2016.03.014.

  6. Gouin F, Odri G, Revert R, Heymann MF, Rédini F. Tumores de células gigantes de los huesos. EMC-Aparato Locomotor. 2012; 45(2): 1-13. doi: 10.1016/s1286-935x(12)61891-7.

  7. Raskin K, Schwab J, Mankin H, Springfield D, Hornicek F. Giant Cell Tumor of Bone. J Am Acad Orthop Surg. 2013; 21(2): 118-26. doi: 10.5435/JAAOS-21-02-118.

  8. Sobti A, Agrawal P, Agarwala S, Agarwal M. Giant Cell Tumor of Bone - An Overview. Arch Bone Jt Surg. 2016; 4(1): 2-9. doi: 10.22038/ABJS.2016.4701.

  9. De la Garza-Montano P, Estrada-Villasenor E, Rubio RD, Martinez-Lopez V, Avila-Luna A, Alfaro-Rodriguez A, et al. Epidemiological aspects of osteosarcoma, giant cell tumor and chondrosarcoma musculoskeletal tumors. Experience of the National Rehabilitation Institute, Mexico City. Asian Pac J Cancer Prev. 2015; 16(15): 6451-5. doi: 10.7314/apjcp.2015.16.15.6451.

  10. Estrada-Villaseñor E, Linares-González L, Delgado-Cedillo E, González-Guzmán R, Rico-Martínez G. Prevalencia y características clínico-patológicas del tumor de células gigantes. Acta Ortop. Mex. 2015; 29(6): 295-8. doi: n/a.

  11. Verschoor AJ, Bovée JVMG, Mastboom MJL, Dijkstra PDS, Michiel AJ Van De Sande, Gelderblom H. Incidence and demographics of giant cell tumor of bone in The Netherlands: first nationwide pathology registry study. Acta Orthop. 2018; 89(5): 570-4. doi: 10.1080/17453674.2018.1490987.

  12. Rockberg J, Bach BA, Amelio J, Hernandez RK, Sobocki P, Engellau J, et al. Incidence Trends in the Diagnosis of Giant Cell Tumor of Bone in Sweden Since 1958. J Bone Joint Surg Am. 2015; 97(21): 1756-66. doi: 10.2106/JBJS.O.00156.

  13. Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2010; 8(10): 705-18. doi: n/a.

  14. López P, Álvarez S, González JL. Actualización del osteosarcoma para el médico de familia. SEMERGEN-Medicina de Familia. 2011; 37(1): 1-52. doi: 10.1016/j.semerg.2010.06.008.

  15. Bindiganavile S, Han I, Yun JY, Kim H-S. Long-term outcome of chondrosarcoma: a single institutional experience. Cancer Res Treat. 2015; 47(4): 897-903. doi: 10.4143/crt.2014.135.

  16. Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res. 2011; 469(2): 591-9. doi: 10.1007/s11999-010-1501-7.

  17. Gouin F, Dumaine V; French Sarcoma and Bone Tumor Study Groups GSF-GETO. Local recurrence after curettage treatment of giant cell tumors in peripheral bones: retrospective study by the GSF-GETO (French Sarcoma and Bone Tumor Study Groups). Orthop Traumatol Surg Res. 2013; 99(6 Suppl): S313-8. doi: 10.1016/j.otsr.2013.07.006.




2020     |     www.medigraphic.com